Relief for Pfizer as Indian Sutent case heads back to patent office
This article was originally published in Scrip
Executive Summary
The Supreme Court of India has set aside a patent revocation order against Pfizer's anticancer Sutent (sunitinib malate), remanding the case back to the patent office following certain procedural lapses.